DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables.
Dentsply Sirona stock last closed at $11.81, up 0.51% from the previous day, and has decreased 15.22% in one year. It has underperformed other stocks in the Medical Instruments & Supplies industry by 0.09 percentage points. Dentsply Sirona stock is currently +19.9% from its 52-week low of $9.85, and -31.26% from its 52-week high of $17.18.
At the moment, there are 199.75M XRAY shares outstanding. The market value of XRAY is $2.36B. In the past 24 hours, 3.53M XRAY shares were traded.
You need an online brokerage account in order to access the NASDAQ market and buy XRAY stock.
Based on our research, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, the next step is to fill out some personal information so you can invest in XRAY stock today.
Now that you've finished signing up on our top ranked stock market app, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing money into your investment account.
Once you have selected the best place to buy Dentsply Sirona stock, it's absolutely critical to evaluate their stock prior to investing, so you actually comprehend the risk as well as the opportunity.
WallStreetZen was created to help average investors do more accurate fundamental analysis quickly.
You can see all of the due diligence checks on XRAY's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge XRAY's true value.
Using relative valuations ratios:
You can do more valuation research on XRAY's stock here.
Out of 10 Wall Street analysts who monitor XRAY, the consensus analyst rating on XRAY is a Hold
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Jeffrey Johnson, a bottom 39% analyst from Baird maintains XRAY with a hold rating and raises their XRAY price target from $12.00 to $14.00, on Feb 27, 2026.
Michael Cherny, a top 13% analyst from Bank of America upgrades XRAY to a strong buy rating and raises their XRAY price target from $13.00 to $17.00, on Feb 19, 2026.
Bank of America's Michael Cherny upgraded their rating on Dentsply Sirona (NASDAQ: XRAY) from Hold to Strong Buy on 2026/02/19. The analyst also raised their price target by 30.8% from $13 to $17.
Dentsply Sirona will report its Q4 and FY 2025 earnings on 2025/02/26.
Upgrading the stock and raising their price target in a preview note, Cherny said that management's upcoming guidance "could be a clearing event" such that the risk/reward on the stock "finally skews positive."
The print could cause volatility if management cuts the dividend, commits to elevated investments, and introduces consensus-missing guidance, the analyst noted.
Cherny called any post-print dip in the stock price an attractive buying opportunity because "those decisions and progress in repairing distributor relationships could support medium-term growth stabilization."
Kevin Caliendo, a top 19% analyst from UBS maintains XRAY with a strong buy rating and lowers their XRAY price target from $17.00 to $16.00, on Feb 3, 2026.
Glen Santangelo, a bottom 10% analyst from Barclays initiates coverage on XRAY with a strong sell rating and announces their XRAY price target of $12.00, on Dec 9, 2025.
Lilia-Celine Lozada, a top 47% analyst from JP Morgan maintains XRAY with a hold rating and lowers their XRAY price target from $14.00 to $12.00, on Nov 7, 2025.
You can dive deeper into what analysts are forecasting on the Dentsply Sirona stock forecast page.
Last year, XRAY revenue was $3.68B. In the last five year, XRAY's revenue has increased by 1.96% per year. This was slower than the Medical Instruments & Supplies industry average of 19.07%.
Dig into XRAY's earnings and revenue performance here.
In the past 12 months, insiders at XRAY have sold more shares than they have bought.
James D. Forbes, Director of XRAY, was the latest XRAY insider to buy. They bought $62,400.00 worth of XRAY shares on Mar 9, 2026.
Learn more about who owns XRAY stock here.
No, Dentsply Sirona doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
There are two main types of orders:
Hit the Open button and your broker will execute your order.
If you want more help with investing in stocks on eToro, watch the helpful video below:
Now that you own some XRAY shares, you'll want to stay up-to-date on your new investment.
Create a watchlist to get notified of the latest news about your XRAY stock.
To reiterate, here are the 6 steps to buy stock in Dentsply Sirona:
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to watch your new investment in Dentsply Sirona, create your watchlist below.